
  
    
      
        Background_NNP
        The_DT actin_NN cytoskeleton_NN is_VBZ a_DT dynamic_JJ system_NN composed_VBN of_IN
        actin_NN filaments_NNS ,_, proteins_NNS that_WDT regulate_VB filament_NN dynamics_NNS ,_,
        and_CC proteins_NNS that_WDT remodel_NN and_CC make_VB use_NN of_IN the_DT cytoskeletal_NN
        network_NN ._. An_DT important_JJ aspect_NN of_IN actin_NN cytoskeletal_NN research_NN
        has_VBZ been_VBN the_DT use_NN of_IN small_JJ molecules_NNS that_WDT affect_VBP actin_NN
        dynamics_NNS and_CC proteins_NNS that_WDT act_NN on_IN the_DT cytoskeleton_NN [_NN 1_CD ]_NN ._.
        2_CD ,_, 3_CD -_: butanedione_NN monoxime_NN (_( BDM_NNP )_) is_VBZ a_DT small_JJ molecule_NN that_IN
        inhibits_NNS the_DT ATPase_NNP activity_NN of_IN muscle_NN myosinII_NN and_CC reduces_VBZ
        the_DT force_NN generated_VBN by_IN this_DT motor_NN protein_NN [_NN 2_CD 3_CD ]_NN ._. BDM_NNP was_VBD
        introduced_VBN to_TO the_DT cell_NN biology_NN community_NN as_IN a_DT millimolar_NN
        inhibitor_NN of_IN multiple_JJ non-muscle_JJ myosins_NNS with_IN greatest_JJS
        potency_NN in_IN inhibiting_VBG non-muscle_JJ myosinII_NN [_NN 4_CD ]_NN ._. It_PRP was_VBD
        subsequently_RB used_VBN ,_, in_IN concert_NN with_IN other_JJ approaches_NNS ,_, to_TO
        study_VB nm-myosin_JJ II_NNP function_NN in_IN a_DT variety_NN of_IN biological_JJ
        processes_VBZ [_NN 5_CD 6_CD 7_CD 8_CD ]_NN ._. BDM_NNP was_VBD recently_RB shown_VBN not_RB to_TO
        inhibit_VB any_DT non-muscle_JJ myosins_NNS so_RB far_RB tested_VBN ,_, leaving_VBG the_DT
        question_NN of_IN how_WRB it_PRP affects_VBZ cells_NNS unanswered_JJ [_NN 9_CD 10_CD ]_NN ._.
        One_CD process_NN inhibited_VBD by_IN BDM_NNP is_VBZ the_DT centripetal_NN flow_NN of_IN
        actin_NN from_IN the_DT leading_VBG edge_NN into_IN the_DT cell_NN body_NN ,_, known_VBN as_IN
        retrograde_NN flow_NN [_NN 11_CD 12_CD ]_NN ._. Retrograde_NNP flow_NN is_VBZ thought_VBN to_TO
        be_VB driven_VBN by_IN a_DT "_'' push-pull_JJ "_'' mechanism_NN of_IN polymerization_NN of_IN
        actin_NN at_IN the_DT leading_VBG edge_NN of_IN the_DT cell_NN and_CC contractile_NN
        activity_NN of_IN myosin_NN motor_NN proteins_NNS [_NN 13_CD 14_CD ]_NN ._. Formation_NNP of_IN
        new_JJ actin_NN filaments_NNS is_VBZ predominantly_RB mediated_JJ by_IN the_DT
        nucleation_NN activity_NN of_IN the_DT Arp_NNP 2_CD /_NN 3_CD complex_JJ [_NN 15_CD ]_NN ._. Members_NNS
        of_IN the_DT WASP_NNP /_NN WAVE_NNP family_NN of_IN proteins_NNS ,_, among_IN others_NNS ,_,
        stimulate_VB and_CC regulate_VB the_DT Arp_NNP 2_CD /_NN 3_CD complex_JJ for_IN spatial_NN and_CC
        temporal_JJ control_NN of_IN filament_NN nucleation_NN [_NN 15_CD ]_NN ._.
        Localization_NNP of_IN these_DT proteins_NNS to_TO the_DT leading_VBG edge_NN ,_, though_IN
        not_RB completely_RB understood_VBN ,_, is_VBZ probably_RB mediated_JJ through_IN
        their_PRP$ interactions_NNS with_IN the_DT actin_NN cytoskeleton_NN itself_PRP and_CC
        membrane-associated_JJ binding_JJ partners_NNS [_NN 15_CD 16_CD ]_NN ._.
        Inhibition_NNP of_IN retrograde_NN flow_NN by_IN BDM_NNP has_VBZ been_VBN used_VBN as_IN
        evidence_NN for_IN the_DT role_NN of_IN nm-myosins_JJ in_IN retrograde_NN flow_NN [_NN 12_CD
        ]_NN ._. Though_IN not_RB explicitly_RB stated_VBN ,_, the_DT localization_NN and_CC
        importance_NN of_IN nm-myosin_JJ II_NNP in_IN multiple_JJ cell_NN types_NNS ,_, and_CC the_DT
        fact_NN that_IN BDM_NNP was_VBD thought_VBN to_TO have_VB greatest_JJS potency_NN in_IN
        inhibiting_VBG nm-myosin_JJ II_NNP has_VBZ led_VBN most_JJS to_TO look_VB at_IN BDM_NNP 's_POS effect_NN
        on_IN retrograde_NN flow_NN as_IN a_DT result_NN of_IN inhibiting_VBG this_DT protein_NN ._.
        [_NN 11_CD 17_CD 18_CD ]_NN ._. A_DT role_NN for_IN nm-myosin_JJ II_NNP may_MD exist_VB ,_, given_VBN its_PRP$
        localization_NN and_CC that_IN other_JJ perturbations_NNS that_WDT affect_VBP
        myosin_NN function_NN -_: myosin_NN S_NNP 1_CD microinjection_NN ,_, ML-_NNP 7_CD treatment_NN ,_,
        and_CC expression_NN of_IN dominant_JJ negative_JJ nm-myosin_JJ II_NNP constructs_NNS
        and_CC have_VBP similar_JJ effects_NNS to_TO BDM_NNP treatment_NN [_NN 5_CD 7_CD 12_CD ]_NN ._.
        However_RB ,_, a_DT study_NN in_IN chick_NN dorsal_NN root_NN ganglia_NN neurons_NNS where_WRB
        nm-myosin_JJ II_NNP was_VBD inactivated_JJ using_VBG chromophore_NN assisted_VBN
        laser_NN inactivation_NN saw_VBD no_DT effect_NN on_IN retrograde_NN flow_NN rates_NNS [_NN
        19_CD ]_NN ._. We_PRP know_VBP now_RB that_IN BDM_NNP does_VBZ not_RB in_IN fact_NN inhibit_VB
        nm-myosin_JJ II_NNP ._. So_RB ,_, is_VBZ this_DT effect_NN that_IN we_PRP see_VBP with_IN BDM_NNP
        mediated_JJ by_IN other_JJ proteins_NNS involved_VBN in_IN retrograde_NN flow_NN ?_. And_CC
        what_WP can_MD this_DT tell_VB us_PRP about_IN the_DT mechanism_NN of_IN retrograde_NN
        flow_NN ?_. How_WRB similar_JJ is_VBZ this_DT process_NN to_TO other_JJ actin_NN mediated_JJ
        processes_NNS that_DT use_NN these_DT same_JJ proteins_NNS ,_, such_JJ as_IN Listeria_NNP
        motility_NN ?_. BDM_NNP has_VBZ a_DT clear_JJ effect_NN on_IN a_DT number_NN of_IN cell_NN
        biological_JJ processes_NNS ._. Understanding_NNP how_WRB these_DT effects_NNS are_VBP
        mediated_JJ can_MD help_VB us_PRP learn_VB from_IN BDM_NNP and_CC reinterpret_NN
        experiments_NNS that_WDT made_VBD use_NN of_IN it_PRP ,_, while_IN working_VBG to_TO find_VB new_JJ
        and_CC better_JJR inhibitors_NNS ._.
      
      
        Results_NNS
        
          BDM_NNP inhibits_NNS actin_NN incorporation_NN in_IN mammalian_JJ
          cells_NNS
          BDM_NNP has_VBZ been_VBN reported_VBN to_TO not_RB inhibit_VB nm-myosin_JJ II_NNP
          ATPase_NNP activity_NN [_NN 9_CD ]_NN ._. We_PRP show_VBP data_NNS [_NN Figure_NN 1_CD A_DT ]_NN that_WDT
          supports_VBZ this_DT report_NN ._. The_DT ATPase_NNP activity_NN of_IN platelet_NN
          nm-myosin_JJ II_NNP S_NNP 1_CD fragment_NN ,_, is_VBZ not_RB inhibited_VBD by_IN BDM_NNP while_IN
          the_DT inhibitor_NN ,_, blebbistatin_NN ,_, decreases_NNS ATPase_NNP activity_NN by_IN
          more_JJR than_IN 90_CD %_NN ._. The_DT stimulation_NN of_IN ATPase_NNP activity_NN by_IN BDM_NNP
          [_NN Figure_NN 1_CD A_DT ]_NN is_VBZ similar_JJ to_TO a_DT ~_NN 2_CD fold_VB increase_NN seen_VBN
          previously_RB (_( A_DT ._. Straight_NNP personal_JJ communication_NN )_) ._.
          Though_IN BDM_NNP does_VBZ not_RB inhibit_VB nm-myosin_JJ II_NNP ,_, in_IN
          permeabilized_JJ yeast_NN (_( 
          S_NNP ._. cerviseae_NN )_) BDM_NNP has_VBZ been_VBN shown_VBN
          to_TO decrease_VB incorporation_NN of_IN exogenous_JJ actin_NN into_IN the_DT
          cytoskeleton_NN [_NN 20_CD ]_NN ._. This_DT process_NN of_IN actin_NN incorporation_NN
          requires_VBZ proteins_NNS involved_VBN in_IN actin_NN filament_NN formation_NN
          and_CC proteins_NNS that_WDT may_MD localize_NN a_DT nucleation_NN complex_JJ [_NN 20_CD
          21_CD ]_NN ._. To_TO determine_VB if_IN BDM_NNP has_VBZ a_DT similar_JJ effect_NN on_IN actin_NN
          incorporation_NN in_IN mammalian_JJ cells_NNS ,_, and_CC if_IN so_IN an_DT effect_NN on_IN
          actin_NN nucleation_NN ,_, spreading_VBG Swiss_JJ 3_CD T_NN 3_CD cells_NNS were_VBD treated_VBN
          briefly_NN with_IN a_DT media_NNS control_VBP or_CC 15_CD mM_NN BDM_NNP and_CC then_RB
          permeabilized_JJ with_IN the_DT detergent_NN saponin_NN in_IN the_DT presence_NN
          of_IN fluorescently_RB labeled_VBN actin_NN ._. The_DT cells_NNS were_VBD then_RB fixed_VBN
          and_CC incorporation_NN of_IN exogenous_JJ actin_NN was_VBD determined_VBN by_IN
          fluorescence_NN microscopy_NN [_NN 22_CD ]_NN ._. Control_NNP cells_NNS show_VBP
          fluorescent_NN incorporation_NN at_IN the_DT periphery_NN ,_, or_CC leading_VBG
          edge_NN ,_, of_IN the_DT cell_NN [_NN Figure_NN 1_CD B_NNP ]_NN ._. Treatment_NNP of_IN cells_NNS with_IN 15_CD
          mM_NN BDM_NNP for_IN one_CD minute_NN blocked_VBD incorporation_NN at_IN the_DT
          leading_VBG edge_NN ,_, as_IN seen_VBN by_IN the_DT lack_NN of_IN fluorescence_NN
          intensity_NN ,_, without_IN significant_JJ effects_NNS on_IN cell_NN morphology_NN
          [_NN Figure_NN 1_CD B_NNP ]_NN ._. Cells_NNP that_WDT remained_VBD flat_JJ and_CC were_VBD not_RB
          disrupted_VBN by_IN the_DT permeabilization_NN process_NN were_VBD counted_VBN ,_,
          and_CC more_JJR than_IN 75_CD %_NN (_( 3_CD trials_NNS )_) showed_VBD decreased_VBN
          fluorescence_NN similar_JJ to_TO that_DT seen_VBN in_IN Figure_NN 1_CD B_NNP (_( cells_NNS that_WDT
          showed_VBD significant_JJ perturbation_NN by_IN the_DT permeabilization_NN
          process_NN did_VBD not_RB show_VB greater_JJR actin_NN incorporation_NN )_) ._.
          Incubation_NNP in_IN BDM_NNP for_IN longer_JJR than_IN 1_CD minute_NN caused_VBN more_RBR
          pronounced_JJ morphological_JJ change_NN upon_IN permeabilization_NN ,_,
          and_CC one-minute_JJ treatment_NN was_VBD used_VBN for_IN subsequent_JJ
          experiments_NNS ._.
          As_IN a_DT control_NN ,_, cytochalasin_NN D_NNP ,_, a_DT small_JJ molecule_NN that_IN
          inhibits_NNS actin_NN dynamics_NNS by_IN capping_VBG the_DT growing_VBG ends_NNS of_IN
          actin_NN filaments_NNS ,_, was_VBD added_VBN to_TO cells_NNS ._. If_IN added_VBD prior_RB to_TO
          permeabilization_NN but_CC not_RB during_IN ,_, exogenous_JJ actin_NN was_VBD
          still_RB able_JJ to_TO incorporate_VB into_IN permeabilized_JJ cells_NNS and_CC
          fluorescence_NN incorporation_NN was_VBD high_JJ ,_, similar_JJ to_TO control_VB
          cells_NNS [_NN Figure_NN 1_CD ]_NN ._. As_IN cytochalasin_NN D_NNP has_VBZ a_DT high_JJ affinity_NN
          (_( 50_CD nM_NN )_) for_IN the_DT growing_VBG ends_NNS of_IN actin_NN filaments_NNS ,_, this_DT
          treatment_NN should_MD inhibit_VB polymerization_NN of_IN existing_VBG
          filaments_NNS but_CC should_MD not_RB block_VB new_JJ filament_NN formation_NN [_NN
          23_CD ]_NN ._. Thus_RB the_DT actin_NN incorporated_VBN most_RBS likely_JJ reflects_VBZ
          nucleation_NN of_IN new_JJ filaments_NNS ,_, as_RB previously_RB discussed_VBN [_NN 24_CD
          ]_NN ._. As_IN expected_VBN ,_, cells_NNS treated_VBN with_IN cytochalasin_NN D_NNP during_IN
          permeabilization_NN showed_VBD no_DT actin_NN incorporation_NN (_( data_NNS not_RB
          shown_VBN )_) ._.
          To_TO determine_VB if_IN BDM_NNP was_VBD affecting_VBG actin_NN dynamics_NNS
          directly_RB ,_, we_PRP assayed_JJ its_PRP$ ability_NN to_TO inhibit_VB 
          in_IN vitro_NN actin_NN assembly_NN ._. No_DT effect_NN
          was_VBD seen_VBN on_IN the_DT polymerization_NN of_IN actin_NN alone_RB or_CC as_IN
          stimulated_VBN by_IN VCA-activated_NNP Arp_NNP 2_CD /_NN 3_CD complex_JJ ,_, using_VBG a_DT
          pyrene-actin_JJ polymerization_NN assay_NN (_( data_NNS not_RB shown_VBN )_) ._. This_DT
          result_NN was_VBD supported_VBN by_IN the_DT observation_NN that_IN 
          Listeria_NNP monocytogenes_NNS continue_VBP to_TO
          move_VB intracellularly_RB ,_, as_IN described_VBN below_IN ._.
        
        
          Arp_NNP 3_CD is_VBZ no_DT longer_RB localized_JJ at_IN the_DT leading_VBG edge_NN
          with_IN BDM_NNP treatment_NN
          Since_IN actin_NN incorporation_NN is_VBZ not_RB due_JJ to_TO elongation_NN of_IN
          existing_VBG filaments_NNS and_CC BDM_NNP does_VBZ not_RB affect_VB pure_JJ actin_NN
          dynamics_NNS in_IN vitro_NN ,_, we_PRP examined_VBD the_DT localization_NN of_IN Arp_NNP 3_CD ,_,
          a_DT subunit_NN of_IN the_DT actin_NN nucleation_NN Arp_NNP 2_CD /_NN 3_CD complex_JJ ._. In_IN
          spreading_VBG Swiss_JJ 3_CD T_NN 3_CD cells_NNS and_CC spread_NN BS-C-_NNP 1_CD cells_NNS ,_, Arp_NNP 3_CD
          localized_VBN to_TO the_DT leading_VBG edge_NN of_IN the_DT cell_NN ._. However_RB ,_, after_IN
          treatment_NN with_IN 20_CD mM_NN BDM_NNP for_IN one_CD minute_NN ,_, localization_NN was_VBD
          lost_VBN in_IN over_IN 90_CD %_NN of_IN the_DT cells_NNS [_NN Figure_NN 2_CD A_DT ]_NN ._. Results_NNS for_IN
          BS-C-_NNP 1_CD and_CC Swiss_JJ 3_CD T_NN 3_CD cells_NNS lines_NNS were_VBD equivalent_NN and_CC the_DT
          results_NNS from_IN BS-C-_NNP 1_CD cells_NNS are_VBP shown_VBN here_RB ,_, as_IN they_PRP are_VBP
          used_VBN in_IN subsequent_JJ time-lapse_JJ experiments_NNS ._. Consistent_NNP
          with_IN the_DT inhibition_NN of_IN actin_NN polymerization_NN in_IN the_DT
          permeabilized_JJ cell_NN assay_NN ,_, cells_NNS treated_VBN with_IN BDM_NNP do_VBP not_RB
          show_VB a_DT brightly_RB staining_VBG actin_NN network_NN at_IN the_DT leading_VBG
          edge_NN [_NN Figure_NN 2_CD A_DT ,_, 2_CD B_NNP ]_NN ._. Titration_NNP of_IN BDM_NNP down_IN to_TO 10_CD mM_NN
          showed_VBD the_DT same_JJ loss_NN of_IN localization_NN ;_: however_RB ,_, 2_CD minutes_NNS
          of_IN treatment_NN was_VBD required_VBN to_TO see_VB equivalent_NN loss_NN (_( data_NNS
          not_RB shown_VBN )_) ._. To_TO control_VB for_IN possible_JJ osmotic_JJ effects_NNS of_IN
          BDM_NNP treatment_NN ,_, we_PRP treated_VBD cells_NNS with_IN 20_CD mM_NN urea_NN ,_, and_CC as_IN
          with_IN a_DT media_NNS control_NN ,_, more_JJR than_IN 90_CD %_NN of_IN the_DT cells_NNS showed_VBD
          localization_NN of_IN Arp_NNP 3_CD at_IN the_DT leading_VBG edge_NN ._.
          To_TO determine_VB if_IN inhibition_NN of_IN actin_NN dynamics_NNS alone_RB was_VBD
          sufficient_JJ for_IN the_DT loss_NN of_IN Arp_NNP 3_CD localization_NN ,_, we_PRP treated_VBD
          cells_NNS with_IN cytochalasin_NN D_NNP and_CC examined_VBD the_DT localization_NN
          of_IN Arp_NNP 3_CD ._. Within_IN one_CD minute_NN at_IN 1_CD uM_NN cytochalasin_NN D_NNP ,_, cell_NN
          ruffling_VBG ceased_VBN ,_, yet_RB Arp_NNP 3_CD remained_VBD at_IN the_DT leading_VBG edge_NN
          [_NN Figure_NN 2_CD A_DT ]_NN ._. In_IN fact_NN ,_, Arp_NNP 3_CD staining_VBG at_IN the_DT leading_VBG edge_NN
          was_VBD consistently_RB higher_JJR ._. Combining_NNP cytochalasin_NN D_NNP and_CC
          BDM_NNP ,_, we_PRP saw_VBD localization_NN equivalent_JJ to_TO or_CC greater_JJR than_IN no_DT
          drug_NN treatment_NN [_NN Figure_NN 2_CD A_DT ]_NN ._. Thus_RB ,_, actin_NN dynamics_NNS may_MD be_VB
          required_VBN for_IN the_DT loss_NN of_IN Arp_NNP 3_CD at_IN the_DT leading_VBG edge_NN upon_IN
          BDM_NNP treatment_NN ._.
          As_IN mentioned_VBN ,_, 
          Listeria_NNP infected_JJ cells_NNS were_VBD used_VBN
          to_TO confirm_VB that_IN BDM_NNP does_VBZ not_RB directly_RB affect_VB actin_NN
          dynamics_NNS ._. 
          Listeria_NNP exploit_VB cellular_JJ -_: actin_NN
          polymerization_NN and_CC organization_NN -_: proteins_NNS to_TO move_VB
          intracellularly_RB ._. We_PRP found_VBD that_IN 20_CD mM_NN BDM_NNP does_VBZ not_RB affect_VB
          movement_NN of_IN bacteria_NNS inside_IN treated_VBN cells_NNS [_NN Figure_NN 3_CD A_DT ]_NN
          consistent_JJ with_IN a_DT previous_JJ report_NN [_NN 4_CD ]_NN ._. Interestingly_RB ,_,
          localization_NN of_IN Arp_NNP 3_CD in_IN 
          Listeria_NNP comet_NN tails_NNS is_VBZ unaffected_JJ
          with_IN BDM_NNP treatment_NN [_NN Figure_NN 3_CD B_NNP ]_NN though_IN Arp_NNP 3_CD localization_NN
          at_IN the_DT leading_VBG edge_NN of_IN these_DT cells_NNS is_VBZ disrupted_VBN ._.
        
        
          VASP_NNP and_CC WAVE_NNP are_VBP no_DT longer_RB localized_VBN to_TO the_DT
          leading_VBG edge_NN with_IN BDM_NNP treatment_NN
          To_TO ask_VB whether_IN the_DT loss_NN of_IN leading_VBG edge_NN localization_NN
          was_VBD specific_JJ to_TO the_DT Arp_NNP complex_NN ,_, we_PRP examined_VBD the_DT
          localization_NN of_IN VASP_NNP and_CC WAVE_NNP 1_CD with_IN BDM_NNP treatment_NN ._. Both_DT
          VASP_NNP and_CC WAVE_NNP function_NN in_IN controlling_VBG actin_NN dynamics_NNS at_IN
          the_DT leading_VBG edge_NN -_: VASP_NNP is_VBZ thought_VBN to_TO promote_VB filament_NN
          elongation_NN ,_, and_CC WAVE_NNP ,_, actin_NN nucleation_NN [_NN 25_CD 26_CD ]_NN ._. Both_DT
          VASP_NNP and_CC WAVE_NNP 1_CD were_VBD de-localized_JJ from_IN the_DT leading_VBG edge_NN
          after_IN 1_CD min_NN of_IN BDM_NNP treatment_NN [_NN Figure_NN 4_CD ]_NN ._. Similar_JJ to_TO Arp_NNP 3_CD ,_,
          the_DT localization_NN of_IN these_DT proteins_NNS was_VBD not_RB disrupted_VBN by_IN
          cytochalasin_NN D_NNP treatment_NN ,_, or_CC by_IN the_DT combination_NN of_IN
          cytochalasin_NN D_NNP and_CC BDM_NNP [_NN Figure_NN 4_CD ]_NN ._.
        
        
          Dynamics_NNP of_IN the_DT loss_NN of_IN Arp-_NNP 3_CD localization_NN
          Two_CD possible_JJ mechanisms_NNS for_IN Arp_NNP 2_CD /_NN 3_CD complex_JJ
          de-localization_JJ were_VBD considered_VBN :_: Arp_NNP 2_CD /_NN 3_CD could_MD move_VB back_RB
          from_IN the_DT leading_VBG edge_NN with_IN retrograde_NN flow_NN of_IN actin_NN and_CC
          then_RB be_VB lost_VBN from_IN the_DT filaments_NNS ,_, or_CC it_PRP could_MD simply_RB
          diffuse_NN from_IN the_DT leading_VBG edge_NN ._. To_TO determine_VB the_DT dynamics_NNS
          of_IN loss_NN of_IN Arp_NNP 2_CD /_NN 3_CD complex_JJ localization_NN ,_, we_PRP generated_VBD a_DT
          stable_JJ cell_NN line_NN expressing_VBG Arp_NNP 3_CD -_: GFP_NNP ._. After_IN BDM_NNP
          treatment_NN ,_, we_PRP observed_VBD a_DT uniform_NN decrease_NN in_IN fluorescence_NN
          suggestive_JJ of_IN dissociation_NN and_CC diffusion_NN of_IN Arp_NNP 3_CD ,_, rather_RB
          than_IN de-localization_JJ driven_VBN by_IN retrograde_NN flow_NN [_NN Figure_NN
          5_CD A_DT ]_NN ._. A_DT linescan_NN of_IN the_DT leading_VBG edge_NN shown_VBN in_IN Figure_NN 5_CD A_DT ,_,
          plotted_VBD across_IN time_NN shows_VBZ the_DT pattern_NN and_CC extent_NN of_IN loss_NN
          of_IN fluorescence_NN signal_NN [_NN Figure_NN 5_CD B_NNP ]_NN ._. Fluorescence_NNP levels_NNS
          decrease_VBP gradually_RB with_IN little_JJ or_CC no_DT shift_NN in_IN the_DT peak_NN of_IN
          fluorescence_NN backward_RB ._. By_IN two_CD minutes_NNS ,_, fluorescence_NN
          levels_NNS at_IN the_DT leading_VBG edge_NN are_VBP equivalent_JJ to_TO background_NN ._.
          After_IN washout_NN of_IN BDM_NNP ,_, Arp_NNP 3_CD -_: GFP_NNP localization_NN returns_NNS in_IN
          just_RB over_IN one_CD minute_NN ._. In_IN all_DT cases_NNS ,_, the_DT loss_NN of_IN Arp_NNP 3_CD -_: GFP_NNP
          at_IN the_DT leading_VBG edge_NN was_VBD seen_VBN concomitantly_RB with_IN loss_NN of_IN
          ruffling_VBG and_CC retraction_NN of_IN the_DT leading_VBG edge_NN or_CC as_IN
          de-localization_JJ with_IN slight_JJ retraction_NN ._. We_PRP did_VBD not_RB see_VB
          retrograde_NN flow_NN of_IN the_DT Arp_NNP 3_CD signal_NN in_IN an_DT otherwise_RB stable_JJ
          leading_VBG edge_NN ._.
        
      
      
        Discussion_NNP
        BDM_NNP has_VBZ been_VBN used_VBN to_TO probe_VB actin-dependent_JJ processes_NNS on_IN
        the_DT assumption_NN that_IN it_PRP is_VBZ a_DT specific_JJ inhibitor_NN of_IN mysosins_NNS ._.
        BDM_NNP has_VBZ recently_RB been_VBN found_VBN not_RB to_TO inhibit_VB the_DT 
        in_IN vitro_NN ATPase_NNP activity_NN of_IN human_JJ
        platelet_NN nm-myosin_JJ II_NNP ,_, Acanthamoeba_NNP myosinIc_NN ,_, human_JJ myoIe_NN ,_,
        chicken_NN myosinV_NN ,_, and_CC porcine_NN myosinVI_NN ,_, though_IN it_PRP does_VBZ
        inhibit_VB rabbit_NN muscle_NN myosinII_NN [_NN 9_CD 10_CD ]_NN ._. Thus_RB the_DT
        literature_NN 's_POS interpretations_NNS of_IN BDM_NNP 's_POS effects_NNS are_VBP probably_RB
        incorrect_JJ ._. Our_PRP$ results_NNS suggest_VBP that_IN the_DT effects_NNS of_IN BDM_NNP on_IN
        actin-dependent_JJ processes_VBZ such_JJ as_IN cell_NN motility_NN and_CC
        retrograde_NN flow_NN may_MD result_VB from_IN effects_NNS on_IN proteins_NNS
        involved_VBN in_IN actin_NN polymerization_NN and_CC the_DT leading_VBG edge_NN actin_NN
        itself_PRP ._. It_PRP is_VBZ not_RB clear_JJ if_IN these_DT effects_NNS on_IN leading_VBG edge_NN
        components_NNS are_VBP direct_JJ or_CC indirect_JJ ._. The_DT loss_NN of_IN actin_NN
        polymerization_NN machinery_NN ,_, however_RB ,_, is_VBZ a_DT previously_RB
        un-described_JJ effect_NN of_IN BDM_NNP treatment_NN and_CC this_DT highlights_VBZ
        the_DT importance_NN of_IN defining_VBG the_DT localization_NN of_IN proteins_NNS
        involved_VBN in_IN actin_NN dynamics_NNS when_WRB leading_VBG edge_NN activity_NN is_VBZ
        disrupted_VBN ._.
        BDM_NNP application_NN leads_VBZ to_TO the_DT loss_NN of_IN localization_NN of_IN
        leading_VBG edge_NN components_NNS involved_VBN in_IN actin_NN nucleation_NN ._. We_PRP
        observe_VBP that_IN within_IN two_CD minutes_NNS ,_, application_NN of_IN BDM_NNP leads_VBZ
        to_TO the_DT de-localization_JJ of_IN the_DT leading_VBG edge_NN components_NNS -_:
        Arp_NNP 3_CD ,_, VASP_NNP ,_, and_CC WAVE_NNP -_: and_CC this_DT is_VBZ concurrent_JJ with_IN the_DT loss_NN
        of_IN the_DT actin_NN network_NN at_IN the_DT leading_VBG edge_NN ._. Our_PRP$ data_NNS suggest_VBP
        a_DT mechanism_NN of_IN de-localization_JJ of_IN Arp_NNP 3_CD consistent_JJ with_IN
        dissociation_NN or_CC diffusion_NN rather_RB than_IN retrograde_NN flow_NN ._. We_PRP
        cannot_NN determine_VBP the_DT causal_NN relationship_NN between_IN loss_NN of_IN
        leading_VBG edge_NN components_NNS and_CC loss_NN of_IN the_DT leading_VBG edge_NN actin_NN
        network_NN itself_PRP ._. At_IN the_DT least_JJS ,_, the_DT two_CD occur_VB
        simultaneously_RB ._.
        Interestingly_RB ,_, 
        Listeria_NNP bacteria_NNS continue_VBP to_TO move_VB in_IN
        the_DT presence_NN of_IN BDM_NNP ,_, while_IN the_DT leading_VBG edge_NN of_IN the_DT infected_JJ
        cell_NN stops_VBZ ruffling_VBG ._. Both_DT processes_NNS have_VBP been_VBN shown_VBN to_TO
        involve_VB the_DT Arp_NNP 2_CD /_NN 3_CD complex_JJ ._. That_DT BDM_NNP inhibits_NNS one_CD actin_NN
        dependent_JJ process_NN but_CC not_RB the_DT other_JJ ,_, may_MD be_VB an_DT interesting_JJ
        difference_NN in_IN the_DT location_NN of_IN polymerization_NN within_IN the_DT
        cell_NN -_: actin_NN polymerization_NN at_IN the_DT leading_VBG edge_NN vs_NNS ._. the_DT
        cell_NN body_NN ,_, or_CC a_DT difference_NN in_IN the_DT mechanism_NN of_IN actin_NN
        polymerization_NN -_: the_DT leading_VBG edge_NN vs_NNS ._. a_DT 
        Listeria_NNP bacterium_NN ._. BDM_NNP treatment_NN
        thus_RB seems_VBZ to_TO disrupt_VB actin_NN dynamics_NNS specific_JJ to_TO the_DT plasma_NN
        membrane_NN and_CC this_DT may_MD provide_VB a_DT clue_NN to_TO both_DT the_DT mechanism_NN
        of_IN BDM_NNP inhibition_NN and_CC the_DT relationship_NN of_IN actin_NN dynamics_NNS at_IN
        the_DT plasma_NN membrane_NN ._.
        Current_JJ understanding_NN of_IN the_DT retrograde_NN flow_NN of_IN actin_NN
        has_VBZ been_VBN influenced_VBN by_IN the_DT use_NN of_IN BDM_NNP in_IN the_DT sea_NN urchin_NN
        coelomocyte_NN and_CC 
        Aplysia_NNP bag_NN cell_NN neuron_NN systems_NNS ._. Our_PRP$
        data_NNS are_VBP consistent_JJ with_IN results_NNS in_IN sea_NN urchin_NN coelomocytes_NNS
        where_WRB BDM_NNP phenocopies_NNS the_DT effect_NN of_IN cytochalasin_NN D_NNP ,_,
        blocking_VBG retrograde_NN flow_NN at_IN the_DT leading_VBG edge_NN with_IN continued_JJ
        contraction_NN of_IN the_DT actin_NN network_NN causing_VBG a_DT clearing_NN of_IN
        actin_NN at_IN the_DT leading_VBG edge_NN [_NN 11_CD ]_NN ._. In_IN the_DT coelomyocte_NN
        system_NN ,_, de-localization_JJ of_IN leading_VBG edge_NN components_NNS by_IN BDM_NNP
        could_MD account_VB for_IN the_DT inhibition_NN of_IN actin_NN polymerization_NN
        and_CC clearing_NN ._. In_IN the_DT 
        Aplysia_NNP bag_NN cell_NN neuron_NN ,_, BDM_NNP
        application_NN leads_VBZ to_TO extension_NN of_IN filopodia_NN and_CC the_DT growth_NN
        cone_NN itself_PRP ._. Filopodial_NNP extension_NN was_VBD interpreted_VBN as_IN
        supporting_VBG the_DT clutch_NN model_NN ,_, with_IN myosins_NNS pulling_VBG filaments_NNS
        toward_IN the_DT growth_NN cone_NN interior_JJ ._. When_WRB the_DT myosin_NN activity_NN
        was_VBD blocked_VBN with_IN BDM_NNP treatment_NN ,_, continued_VBD actin_NN
        polymerization_NN ,_, thought_VBD to_TO occur_VB as_IN elongation_NN of_IN existing_VBG
        filaments_NNS ,_, lead_VB to_TO protrusion_NN [_NN 12_CD 27_CD 28_CD ]_NN ._. Our_PRP$
        observation_NN of_IN BDM_NNP activity_NN suggests_VBZ an_DT alternative_JJ
        explanation_NN ._. Perhaps_RB components_NNS required_VBN for_IN nucleation_NN are_VBP
        de-localized_JJ by_IN BDM_NNP allowing_VBG new_JJ polymerization_NN to_TO be_VB
        re-directed_JJ to_TO filopodia_NN ,_, as_IN filopodial_NN extension_NN is_VBZ
        thought_VBN to_TO be_VB driven_VBN by_IN elongation_NN and_CC not_RB nucleation_NN [_NN 27_CD
        ]_NN ._. The_DT extension_NN of_IN the_DT growth_NN cone_NN itself_PRP could_MD result_VB
        from_IN a_DT similar_JJ diversion_NN of_IN actin_NN monomer_NN from_IN nucleation_NN
        of_IN new_JJ filaments_NNS to_TO extension_NN of_IN existing_VBG filaments_NNS ._.
        Treatment_NNP of_IN cells_NNS with_IN BDM_NNP often_RB leads_VBZ to_TO filopodia-like_JJ
        projections_NNS as_IN seen_VBN in_IN Figure_NN 1_CD Band_NNP Figure_NNP 2_CD B_NNP ._. Data_NNS from_IN
        studies_NNS of_IN 
        in_IN vivo_NN and_CC 
        in_IN vitro_NN filopodia_NN formation_NN suggest_VBP
        that_IN they_PRP develop_VBP as_IN a_DT reorganization_NN of_IN the_DT dendritic_JJ
        network_NN in_IN which_WDT they_PRP exist_VBP [_NN 29_CD 30_CD ]_NN ._. In_IN the_DT presence_NN of_IN
        proteins_NNS that_WDT bundle_NN and_CC reorganize_VB actin_NN filaments_NNS into_IN
        filopodial_NN precursors_NNS ,_, the_DT de-localization_JJ of_IN Arp_NNP 2_CD /_NN 3_CD and_CC
        other_JJ leading_VBG edge_NN components_NNS may_MD lead_VB to_TO the_DT formation_NN of_IN
        filopodia_NN ,_, which_WDT are_VBP then_RB elongated_JJ as_IN described_VBN above_IN ._.
        Future_JJ studies_NNS will_MD hopefully_RB clarify_VB the_DT role_NN of_IN actin_NN
        nucleation_NN in_IN the_DT 
        Aplysia_NNP system_NN or_CC alternative_JJ
        mechanisms_NNS that_WDT would_MD reconcile_VB the_DT discrepancies_NNS between_IN
        systems_NNS ._.
        In_IN all_DT systems_NNS ,_, a_DT better_JJR understanding_NN of_IN how_WRB the_DT
        leading_VBG edge_NN is_VBZ constructed_VBN and_CC maintained_VBN will_MD require_VB
        specific_JJ and_CC detailed_JJ descriptions_NNS of_IN the_DT activity_NN and_CC
        localization_NN of_IN the_DT proteins_NNS involved_VBN ._. Membrane_NNP ruffling_VBG ,_,
        often_RB used_VBN as_IN a_DT measure_NN of_IN actin_NN dynamics_NNS at_IN the_DT leading_VBG
        edge_NN ,_, is_VBZ a_DT very_JJ crude_NN readout_NN ._. The_DT sensitivity_NN of_IN the_DT
        leading_VBG edge_NN is_VBZ demonstrated_VBN by_IN the_DT observation_NN that_IN DMSO_NNP
        treatment_NN at_IN a_DT concentration_NN of_IN 1_CD %_NN causes_NNS temporary_JJ
        inhibition_NN of_IN ruffling_VBG and_CC concomitant_NN Arp_NNP 3_CD de-localization_JJ
        (_( Yarrow_NNP unpublished_JJ results_NNS )_) ._. Experimental_NNP approaches_NNS that_WDT
        may_MD help_VB address_VB how_WRB such_JJ a_DT dynamic_JJ and_CC sensitive_JJ structure_NN
        is_VBZ established_VBN and_CC maintained_VBN include_VBP combining_VBG inhibition_NN
        of_IN actin_NN dynamics_NNS with_IN the_DT use_NN of_IN tools_NNS that_WDT affect_VBP Arp_NNP 2_CD /_NN 3_CD
        or_CC myosin_NN activity_NN or_CC localization_NN ,_, in_IN specific_JJ ways_NNS ._.
        Though_IN preliminary_JJ ,_, we_PRP have_VBP seen_VBN that_IN Arp_NNP 3_CD is_VBZ still_RB
        localized_JJ in_IN the_DT presence_NN of_IN latrunculin_NN A_DT and_CC
        jasplakinolide_NN ,_, and_CC that_IN this_DT localization_NN is_VBZ lost_VBN with_IN BDM_NNP
        treatment_NN unlike_IN the_DT combination_NN of_IN cytochalasin_NN D_NNP and_CC BDM_NNP
        (_( Yarrow_NNP unpublished_JJ results_NNS )_) ._. These_DT results_NNS may_MD in_IN the_DT end_NN
        tell_VB us_PRP more_JJR about_IN our_PRP$ understanding_NN of_IN what_WP latrunculin_NN A_DT
        and_CC jasplakinolide_NN do_VBP 
        in_IN vivo_NN than_IN the_DT leading_VBG edge_NN itself_PRP ._.
        Regardless_RB ,_, this_DT type_NN of_IN experiment_NN awaits_VBZ more_RBR specific_JJ
        tools_NNS than_IN BDM_NNP for_IN follow_VB up_RB ._.
        Though_IN BDM_NNP has_VBZ a_DT relatively_RB high_JJ effective_JJ concentration_NN
        (_( in_IN the_DT millimolar_NN range_NN )_) ,_, it_PRP was_VBD widely_RB adopted_VBN by_IN the_DT
        cell_NN biology_NN community_NN because_IN of_IN its_PRP$ rapid_JJ and_CC reversible_JJ
        effect_NN on_IN cell_NN behaviour_NN ._. BDM_NNP has_VBZ not_RB been_VBN exhaustively_RB
        tested_VBN on_IN all_DT myosins_NNS ,_, and_CC a_DT myosin_NN target_NN is_VBZ not_RB
        unreasonable_JJ given_VBN findings_NNS in_IN Acanthomoeba_NNP and_CC 
        S_NNP ._. cerviseae_NN though_IN it_PRP does_VBZ not_RB
        inhibit_VB Acanthamoeba_NNP myosinIc_NN or_CC human_JJ myoIe_NN 
        in_IN vitro_NN [_NN 10_CD 20_CD 21_CD 31_CD ]_NN ._.
        Regardless_RB ,_, we_PRP and_CC others_NNS have_VBP shown_VBN that_IN BDM_NNP is_VBZ not_RB the_DT
        tool_NN that_WDT should_MD be_VB used_VBN to_TO investigate_VB these_DT behaviours_NNS ._.
        The_DT small_JJ molecule_NN approach_NN continues_VBZ to_TO be_VB an_DT effective_JJ
        means_VBZ to_TO develop_VB tools_NNS for_IN understanding_NN cell_NN biological_JJ
        process_NN when_WRB used_VBN and_CC interpreted_VBN appropriately_RB ._. One_CD new_JJ
        compound_NN that_WDT will_MD help_VB clarify_VB the_DT role_NN of_IN nm-myosin_JJ II_NNP is_VBZ
        blebbistatin_NN [_NN 32_CD ]_NN ._. Other_JJ small_JJ molecules_NNS wait_VBP to_TO be_VB
        found_VBN and_CC experiments_NNS using_VBG them_PRP will_MD continuously_RB refine_VB
        our_PRP$ understanding_NN of_IN the_DT leading_VBG edge_NN and_CC the_DT mechanism_NN of_IN
        action_NN of_IN these_DT compounds_NNS ._.
      
      
        Conclusions_NNP
        De-localization_NNP of_IN actin_NN leading_VBG edge_NN components_NNS by_IN BDM_NNP
        treatment_NN is_VBZ a_DT newly_RB described_VBN effect_NN of_IN this_DT compound_NN ._. It_PRP
        may_MD explain_VB results_NNS previously_RB ascribed_VBN to_TO inhibition_NN of_IN
        non-muscle_JJ myosinII_NN by_IN BDM_NNP ,_, particularly_RB in_IN retrograde_NN flow_NN
        studies_NNS ._. Though_IN this_DT effect_NN of_IN BDM_NNP is_VBZ intriguing_JJ ,_, future_JJ
        studies_NNS that_WDT look_VBP at_IN the_DT establishment_NN and_CC maintenance_NN of_IN
        the_DT actin_NN leading_VBG edge_NN should_MD use_VB more_RBR potent_JJ and_CC specific_JJ
        inhibitors_NNS ._.
      
      
        Methods_NNP
        
          Platelet_NNP myosinII_NN ATPase_NNP assay_NN
          The_DT assay_NN was_VBD performed_VBN using_VBG an_DT EnzCheck_NNP phosphate_NN
          release_NN assay_NN (_( Molecular_NNP Probes_NNP )_) ._. Platelet_NNP myosinII_NN S_NNP 1_CD
          was_VBD diluted_VBN to_TO 0_CD ._. 050_CD mg_NN /_NN ml_NN in_IN reaction_NN buffer_NN (_( 0_CD ._. 2_LS M_NNP KCl_NNP ,_,
          10_CD mM_NN Tris_NNP pH_NN 7_CD ._. 0_CD ,_, 10_CD mM_NN CaCl_NNP 
          2_CD ,_, 2_CD mM_NN MgCl_NNP 
          2_CD ,_, 1_CD mM_NN DTT_NNP ,_, 0_CD ._. 2_CD mM_NN
          2_CD -_: amino-_NN 6_CD -_: mercapto-_NN 7_CD -_: methyl_NN purine_NN riboside_NN (_( MESG_NNP )_) in_IN the_DT
          presence_NN of_IN 1_CD U_NNP purine_NN nucleoside_NN phosphorylase_NN (_( PNP_NNP )_) )_) ._.
          DMSO_NNP ,_, 20_CD mM_NN BDM_NNP ,_, or_CC 100_CD uM_NN blebbistatin_NN was_VBD added_VBN to_TO the_DT
          reactions_NNS with_IN a_DT constant_JJ DMSO_NNP concentration_NN of_IN 1_CD %_NN ._. ATP_NNP
          (_( 100_CD uM_NN )_) was_VBD added_VBN to_TO initiate_VB the_DT reaction_NN and_CC
          absorbance_NN at_IN 360_CD nm_NN was_VBD read_VBN every_DT ~_NN 6_CD seconds_NNS for_IN 20_CD
          minutes_NNS ._. BDM_NNP showed_VBD no_DT effect_NN on_IN ATP_NNP hydrolysis_NNS in_IN the_DT
          absence_NN of_IN myosin_NN ._.
        
        
          Tissue_NNP Culture_NNP
          BS-C-_NNP 1_CD cells_NNS and_CC Swiss_JJ 3_CD T_NN 3_CD cells_NNS were_VBD acquired_VBN from_IN the_DT
          ATCC_NNP (_( CCL-_NNP 26_CD ,_, CCL-_NNP 92_CD )_) ._. Cells_NNP were_VBD maintained_VBN in_IN
          Dulbecco_NNP 's_POS Modified_NNP Essential_NNP Medium_NNP with_IN 4_CD ._. 5_CD g_SYM /_NN L_NNP
          glucose_NN ,_, 10_CD %_NN fetal_JJ calf_NN serum_NN ,_, and_CC
          penicillin_NN /_NN streptomycin_NN ._. Cells_NNP were_VBD maintained_VBN at_IN 37_CD °_NN C_NNP
          with_IN 5_CD %_NN CO_NNP 
          2_CD ._.
        
        
          Permeabilized_NNP cell_NN assay_NN
          Permeabilized_NNP cell_NN assays_NNS were_VBD performed_VBN in_IN flow_NN
          chambers_NNS as_RB previously_RB described_VBD [_NN 22_CD ]_NN ._. Swiss_JJ 3_CD T_NN 3_CD cells_NNS
          were_VBD flowed_VBD into_IN the_DT chamber_NN ,_, the_DT chamber_NN inverted_JJ ,_, and_CC
          cells_NNS allowed_VBN to_TO spread_VB for_IN 30_CD -_: 45_CD minutes_NNS in_IN a_DT humidified_JJ
          environment_NN at_IN 37_CD °_NN C_NNP ,_, 5_CD %_NN CO_NNP 
          2_CD ._. The_DT assay_NN was_VBD performed_VBN by_IN adding_VBG
          50_CD ul_NN of_IN the_DT warmed_VBN sample_NN solution_NN to_TO the_DT chamber_NN while_IN
          wicking_VBG with_IN Whatman_NNP paper_NN ._. Cells_NNP were_VBD rinsed_JJ with_IN PBS_NNP ,_,
          treated_VBN with_IN compounds_NNS or_CC media_NNS for_IN 1_CD min_NN ,_, permeabilized_JJ
          in_IN the_DT presence_NN or_CC absence_NN of_IN compound_NN for_IN 3_CD min_NN with_IN
          permeabilization_NN buffer_NN (_( 0_CD ._. 02_CD g_SYM /_NN ml_NN of_IN saponin_NN ,_, 20_CD mM_NN
          HEPES_NNP (_( pH_NN 7_CD ._. 5_LS )_) ,_, 138_CD mM_NN KCl_NNP ,_, 4_CD mM_NN MgCl_NNP 
          2_CD ,_, 3_CD mM_NN ETGA_NNP ,_, 1_CD mM_NN DTT_NNP +_NN protease_NN
          inhibitors_NNS ,_, 0_CD ._. 4_CD uM_NN rhodamine_NN actin_NN ,_, 1_CD mM_NN ATP_NNP )_) ,_, and_CC fixed_VBD
          in_IN PBS_NNP +_NN 3_CD ._. 7_CD %_NN formaldehyde_NN for_IN 10_CD min_NN ._.
        
        
          Listeria_NNP infection_NN
          
          Listeria_NNP monocytogenes_NNS (_( strain_NN
          10403_CD S_NNP )_) were_VBD grown_VBN overnight_JJ in_IN 3_CD mls_NNS of_IN Brain_NNP Heart_NNP
          Infusion_NN media_NNS at_IN room_NN temp_NN without_IN shaking_VBG ._. BS-C-_NNP 1_CD cells_NNS
          on_IN 25_CD mm_NN poly-_NN L-_NNP lysine_NN (_( PLL_NNP )_) coverslips_NNS were_VBD rinsed_JJ with_IN
          media_NNS containing_VBG no_DT antibiotics_NNS and_CC placed_VBN in_IN a_DT 6_CD well_RB
          plate_NN ._. 
          Listeria_NNP were_VBD prepared_VBN by_IN removing_VBG
          1_CD ml_NN of_IN the_DT overnight_JJ culture_NN ,_, pelleting_VBG by_IN a_DT 1_CD min_NN
          Eppendorf_NNP centrifuge_NN spin_NN ,_, washing_VBG the_DT pellet_NN twice_RB with_IN
          antibiotic-free_JJ media_NNS ,_, and_CC resuspending_VBG in_IN 1_CD ml_NN of_IN media_NNS ._.
          10_CD ul_NN of_IN Listeria_NNP were_VBD added_VBN to_TO each_DT well_RB and_CC were_VBD
          allowed_VBN to_TO infect_NN for_IN 1_CD ._. 5_CD hrs_NNS prior_RB to_TO the_DT addition_NN of_IN
          media_NNS containing_VBG 50_CD ug_NN /_NN ml_NN Gentamicin_NNP ._. Cells_NNP were_VBD imaged_JJ
          between_IN 4_CD hrs_NNS and_CC 12_CD hrs_NNS later_RB ._.
        
        
          Compound_NN treatment_NN for_IN immunofluorescence_NN
          Cells_NNP were_VBD allowed_VBN to_TO spread_VB on_IN 18_CD mm_NN round_NN PLL_NNP
          coverslips_NNS in_IN a_DT 12_CD well_RB plate_NN for_IN 30_CD -_: 45_CD minutes_NNS or_CC 2_CD -_: 4_CD
          hours_NNS prior_RB to_TO treatment_NN ._. BDM_NNP (_( Calbiochem_NNP 203984_CD )_) stock_NN
          solution_NN was_VBD made_VBN in_IN media_NNS at_IN 0_CD ._. 5_CD M_NNP and_CC Cytochalasin_NNP D_NNP
          (_( Sigma_NNP C_NNP 8273_CD )_) in_IN DMSO_NNP at_IN 20_CD mM_NN ._. With_IN the_DT plate_NN on_IN a_DT 37_CD °_NN C_NNP
          heat_NN block_NN ,_, appropriately_RB diluted_VBN concentrations_NNS of_IN each_DT
          compound_NN (_( 15_CD or_CC 20_CD mM_NN BDM_NNP ,_, 1_CD uM_NN cytochalasin_NN D_NNP )_) were_VBD made_VBN
          in_IN warmed_VBN media_NNS and_CC added_VBD to_TO cells_NNS after_IN removal_NN of_IN
          existing_VBG media_NNS ._. After_IN 1_CD minute_NN ,_, the_DT cells_NNS were_VBD fixed_VBN for_IN
          immunoflourescence_NN as_IN described_VBN below_IN ._.
        
        
          Immunofluorescence_NNP
          Cells_NNP were_VBD fixed_VBN in_IN a_DT permeabilization_NN /_NN fixation_NN buffer_NN
          (_( 100_CD mM_NN K-P_NNP ipes_NNS pH_NN 6_CD ._. 8_CD ,_, 10_CD mM_NN EGTA_NNP ,_, 1_CD mM_NN MgCL_NNP 2_CD ,_, 0_CD ._. 2_CD %_NN
          TritonX-_NNP 100_CD ,_, 3_CD ._. 7_CD %_NN formaldehyde_NN )_) for_IN 10_CD minutes_NNS ._. For_IN Arp_NNP 3_CD
          immunofluorescence_NN ,_, cells_NNS were_VBD post-fixed_JJ in_IN methanol_NN
          (_( -_: 20_CD °_NN C_NNP )_) for_IN 2_CD minutes_NNS ._. Coverslips_NNP were_VBD rinsed_JJ with_IN TBS_NNP
          containing_VBG 0_CD ._. 1_CD %_NN Triton_NNP X-_NNP 100_CD (_( TBS-Tx_NNP )_) and_CC blocked_VBN in_IN
          TBS-Tx_NNP with_IN 2_CD %_NN BSA_NNP (_( AbDil_NNP )_) for_IN 45_CD minutes_NNS ._. Antibodies_NNP
          were_VBD diluted_VBN in_IN AbDil_NNP and_CC incubated_JJ for_IN 45_CD minutes_NNS ._.
          Coverslips_NNP were_VBD rinsed_JJ in_IN TBS-Tx_NNP and_CC incubated_JJ with_IN
          fluorescently_RB labeled_VBN secondary_JJ antibodies_NNS in_IN TBS-Tx_NNP for_IN
          45_CD minutes_NNS ._. Coverslips_NNP were_VBD rinsed_JJ and_CC mounted_VBD in_IN 90_CD %_NN
          glycerol_NN with_IN 0_CD ._. 5_CD %_NN p-phenylenediamine_JJ in_IN 20_CD mM_NN Tris-p_NNP H_NNP
          8_CD ._. 8_CD ._.
          Antibodies_NNP used_VBD :_: rabbit_NN Arp_NNP 3_CD antibodies_NNS (_( gift_NN from_IN C_NNP ._.
          Egile_NNP using_VBG the_DT same_JJ peptide_NN as_IN described_VBN [_NN 33_CD ]_NN )_) used_VBN
          at_IN 1_CD :_: 500_CD dilution_NN ,_, mouse_NN actin_NN antibodies_NNS (_( Santa_NNP Cruz_NNP
          SC-_NNP 8432_CD )_) used_VBN at_IN 1_CD :_: 10_CD ,_, 000_CD dilution_NN ,_, rabbit_NN VASP_NNP
          antibodies_NNS (_( gift_NN from_IN F_NN ._. Southwick_NNP )_) used_VBN at_IN 1_CD :_: 100_CD ,_, rabbit_NN
          WAVE_NNP 1_CD antibodies_NNS (_( gift_NN from_IN S_NNP ._. Eden_NNP as_IN described_VBN [_NN 26_CD ]_NN )_)
          used_VBN at_IN 1_CD :_: 100_CD and_CC Alexa-dye_NNP labeled_VBD secondary_JJ antibodies_NNS ,_,
          goat_NN anti-rabbit_JJ and_CC goat_NN anti-mouse_JJ (_( Molecular_NNP
          Probes_NNP )_) ._.
        
        
          GFP-Arp_NNP 3_CD cell_NN line_NN
          A_DT stable_JJ BS-C-_NNP 1_CD cell_NN line_NN was_VBD made_VBN by_IN transfection_NN of_IN
          GFP-Arp_NNP 3_CD (_( gift_NN from_IN D_NNP ._. Schafer_NNP as_IN described_VBN [_NN 34_CD ]_NN )_)
          using_VBG Fugene_NNP 6_CD (_( Roche_NNP )_) and_CC selection_NN with_IN 500_CD ug_NN /_NN ml_NN
          Geneticin_NNP ._. GFP_NNP expressing_VBG colonies_NNS were_VBD picked_VBN and_CC
          expanded_VBN ._.
        
        
          Live_JJ imaging_NN of_IN GFP-Arp_NNP 3_CD
          GFP-Arp_NNP 3_CD cells_NNS were_VBD split_VBN onto_IN 25_CD mm_NN PLL_NNP coated_JJ
          coverslips_NNS 4_CD -_: 6_CD hrs_NNS before_IN imaging_NN ._. Cells_NNP were_VBD transferred_VBN
          to_TO Liebovitz_NNP L-_NNP 15_CD media_NNS with_IN 10_CD %_NN fetal_JJ calf_NN serum_NN in_IN a_DT
          heated_JJ (_( 37_CD °_NN C_NNP )_) open-air_JJ chamber_NN 15_CD minutes_NNS prior_RB to_TO
          imaging_NN ._. Images_NNP were_VBD captured_VBN on_IN a_DT Nikon_NNP TE_NNP 300_CD inverted_VBN
          microscope_NN with_IN appropriate_JJ neutral_JJ density_NN filtering_VBG
          using_VBG an_DT Apo_NNP 100_CD ×_NN /_NN 1_CD ._. 4_LS NA_NNP oil_NN emersion_NN phase_NN objective_NN
          and_CC captured_VBN on_IN a_DT CCD_NNP camera_NN (_( Hammamatsu-_NNP OrcaER_NNP )_) using_VBG
          Metamorph_NNP software_NN ._. Images_NNP were_VBD taken_VBN every_DT 15_CD s_VBZ with_IN an_DT
          exposure_NN of_IN 200_CD -_: 1000_CD ms_NNS ._.
        
      
      
        Authors_NNP '_'' contributions_NNS
        JY_NNP prepared_VBD the_DT manuscript_NN and_CC performed_VBD the_DT time-lapse_JJ
        microscopy_NN ,_, 
        Listeria_NNP ,_, and_CC myosin_NN ATPase_NNP
        experiments_NNS ._. Remaining_VBG experimentswere_NN done_VBN in_IN
        collaboration_NN with_IN TL_NNP ._. RL_NNP and_CC TM_NNP supervised_VBD this_DT work_NN and_CC
        provided_VBN funding_NN and_CC support_NN ._. All_DT authors_NNS read_VBP and_CC approved_VBD
        the_DT final_JJ manuscript_NN ._.
      
    
  
